Tillman Gerngross (Adagio)
November 15, 2021 10:45 AM EST
Coronavirus

Covid-19 roundup: Ada­gio plans to sub­mit EUA by Q2 in 2022; HIPRA to en­ter PhII tri­als

Josh Sullivan

Ada­gio plans to sub­mit an EUA for its mon­o­clon­al an­ti­body against Covid-19 in Q2 2022, the com­pa­ny an­nounced in its Q3 up­date.

The sub­mis­sion will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Stem cell start­up spun out of George Church’s lab rais­es $75M

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times